

SARS-CoV-2 reinfections during the first three major COVID-19 waves in Bulgaria

GEORGI K. MARINOV¹, MLADEN MLADENOV², ANTONI RANGACHEV^{3,4}, AND IVAILO ALEXIEV⁵

¹*Department of Genetics, Stanford University, Stanford, CA 94305, USA*

²*Premier Research, Morrisville, NC 27560, USA*

³*Institute of Mathematics and Informatics, Bulgarian Academy of Sciences, Sofia 1113, Bulgaria*

⁴*International Center for Mathematical Sciences-Sofia*

⁵*National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria*

Abstract

Background: The COVID-19 pandemic has had a devastating impact on the world over the past two years (2020-2021). One of the key questions about its future trajectory is the protection from subsequent infections and disease conferred by a previous infection, as the SARS-CoV-2 virus belongs to the coronaviruses, a group of viruses the members of which are known for their ability to reinfect convalescent individuals. Bulgaria, with high rates of previous infections combined with low vaccination rates and an elderly population, presents a somewhat unique context to study this question.

Methods: We use detailed governmental data on registered COVID-19 cases to evaluate the incidence and outcomes of COVID-19 reinfections in Bulgaria in the period between March 2020 and early December 2021.

Results: For the period analyzed, a total of 4,106 cases of individuals infected more than once were observed, including 31 cases of three infections and one of four infections. The number of reinfections increased dramatically during the Delta variant-driven wave of the pandemic towards the end of 2021. We observe a moderate reduction of severe outcomes (hospitalization and death) in reinfections relative to primary infections, and a more substantial reduction of severe outcomes in breakthrough infections in vaccinated individuals.

Conclusions: In the available datasets from Bulgaria prior infection appears to provide some protection from severe outcomes. In contrast, the severity of breakthrough infections was more strongly reduced compared to primary infections in the unvaccinated, although that effect diminished in the higher age groups.

Introduction

The COVID-19¹⁻³ pandemic has become the most significant public health crisis in more than a century, and is still rapidly developing. An important question for its future trajectory, especially given the large and steadily growing number of infected individuals in most countries, is the degree of protection from subsequent infection and serious disease that prior SARS-CoV-2 infection and recovery confers.

SARS-CoV-2 belongs to the coronavirus family, of which four different endemic human viruses were known prior to the pandemic – HCoV-OC43^{4,5}, HCoV-229E⁶, HCoV-NL63^{7,8} and HCoV-HKU1⁹⁻¹¹. These usually cause common colds (around 10-15% of colds, depending on the source¹²⁻¹⁵, are considered to be caused by them), and, as is common with respiratory viruses¹⁶, they cause repeated reinfections throughout people’s lifetimes¹⁷. Large coron-

avirus epidemics are thought to occur at two- to three-year intervals^{18,19}, though these are generally not noticed by society due to the overall mild nature of these viruses.

Given that SARS-CoV-2 belongs to the same family of viruses, it’s natural to expect that a similar host-pathogen dynamics involving frequent reinfections will be observed with it, too.

The first reports of repeated infections appeared very early in the pandemic²⁰, but at the time it was difficult to exclude the possibility of simple persistence of viral RNA as opposed to true reinfections. Viral genomic sequencing (showing that distinct viral lineages infected the same individual more than once) eventually proved beyond reasonable doubt that reinfection occurs but it was still initially seen as an exotic and surprising phenomenon²¹⁻²⁷. Since then, however, reinfection has been proven to be far from a rare phenomenon as a large body of case reports has ac-

cumulated from around the world^{28–122}, most recently including even cases of third infections^{38,123,124}.

A number of cohort studies have also been published^{124–175} but most of these suffer from various drawbacks, such as the inclusion of a very narrow time window after initial infection, focus on healthcare workers (meaning that the age distribution is not representative of the overall population), and the fact that most such studies were carried out prior to the appearance of the more highly derived SARS-CoV-2 variants that have come to dominate the pandemic in 2021 and 2022. The importance of comprehensive population sampling was shown by a recent reinfection study from Denmark¹²⁸, which found protection from reinfection of only 47.1% among those 65 years old and older during the late-2020 surge as opposed to 80.5% for the general population. The importance of variants was first stressed by the placebo trial of the Novavax vaccine in South Africa¹⁷⁶, which showed no protection of prior infection against infection with the dominant at the time there B.1.351 variant¹⁷⁷.

Later, in the end of 2021, the Omicron variant emerged, with a very high degree of immune escape^{178–181} and the ability to reinfect convalescent individuals at a high rate^{124,182?–185}.

In this work, we analyze available reinfection data in Bulgaria prior to the emergence of the Omicron variant, when largely homologous antigenically variants were circulating. Bulgaria has been one of the most seriously affected by the pandemic countries¹⁸⁶, having experienced three major COVID-19 waves in 2020–2021 and exhibiting excess mortality approaching 1% of its population within that period¹⁸⁷. In the same time, only a small portion of the population has been fully vaccinated ($\leq 30\%$ by the end of 2021), meaning that the country provides a unique context in which the clinical impact of reinfections can be observed in a previously severely impacted population with an age structure skewed towards the elderly individuals, but without the confounding factor of high vaccination coverage. We identify 4,106 reinfected individuals out of $\leq 700,000$ cases in the country prior to December 2021. The frequency of reinfection increased substantially during the third wave driven by the Delta variant, at which point reinfections represented $\sim 2.2\%$ of cases, with protection conferred by previous infection $\sim 81\%$. The severity of reinfections (i.e. the rate of hospitalizations and fatalities) was comparable to that of primary infections, while severity was reduced in breakthrough infections in vaccinated uninfected subjects.

Methodology

Datasets

Primary SARS-CoV-2 Infections in Bulgaria

At the time of writing this manuscript, there were no publicly available age-stratified datasets on hospitalizations and deaths associated with confirmed SARS-CoV-2 infections

in Bulgaria. We obtained a patient-sensitive dataset from Bulgaria’s Ministry of Health, which included data on all infections from the beginning of the pandemic until November 5th 2021.

This dataset included information about a person’s age, gender, region, the date of their latest Covid-19 test, their status (infected, recovered, hospitalized, deceased), their hospitalization start and end dates, if any, information about accompanying diseases, as well as whether they received any breathing assistance, whether they were taken into intensive care and whether they died of Covid-19.

Data on breakthrough infections in vaccinated individuals

Information about infections, hospitalizations and deaths among the vaccinated population in Bulgaria were obtained through publicly available datasets provided by Bulgaria’s Ministry of Health. These datasets present a daily time series that contain information about the age at 10 year intervals, gender, vaccination course and count of infected, hospitalized or deceased per group.

Reinfections

No publicly available datasets about the reinfection rates in Bulgaria existed prior to the writing of this manuscript. We obtained these datasets through a separate request for information on patient-sensitive data from Bulgaria’s Ministry of Health. The data provided by the Ministry covers the period from the beginning of the pandemic until December 9th 2021.

Reinfections were defined as cases of two positive tests spaced ≥ 90 days apart.

Breakthrough reinfections were defined as cases of a second positive tests at least one day after the completion of the vaccination course.

SARS-CoV-2 sequencing data

Information about sequenced SARS-CoV-2 genomes was obtained from the GISAID database¹⁸⁸.

Data Availability

All datasets and associated code can be found at <https://github.com/Mlad-en/Cov-Reinfections>.

The dataset containing reinfections has been blinded to protect individuals medical history and is compliant with General Data Protection Regulation (GDPR) data processing.

Results

Suspected SARS-CoV-2 reinfection cases in Bulgaria

In order to identify SARS-CoV-2 reinfection cases in Bulgaria, we obtained datasets on the incidence and clinical




Figure 1: Suspected SARS-CoV-2 reinfections Bulgaria over time. (A) Primary infections in Bulgaria over time. Bulgaria has so far experienced three distinct major epidemiological waves of COVID-19, with peaks in November 2020, March 2021, and October 2021 (an initial wave did occur in the first half of 2020 but it was very small and generally successfully suppressed and is of little relevance to the progression of the pandemic in the country). (B) Number people eligible to be considered for reinfection, i.e. people who have tested positive and ≥ 90 days have elapsed since that positive test. (C) Dominant variants in Bulgaria over time. The first major wave was driven by early B.1/B.1.* derivative variants. The second wave was associated with the Alpha/B.1.1.7 variant. The third wave was dominated by the Delta/B.1.617.2 variant and its AY.* sublineages. (D) Number of probable reinfections over time in Bulgaria (per week).




Figure 2: Time between primary infections and reinfections against the background of different SARS-CoV-2 variants. (A) Distribution of the length of the interval between primary infection and reinfection. (B) Primary infections and reinfections by wave and dominant variant. Waves were defined as follows: “initial infections” refers to the period prior to September 2020; “1st wave” refers to the period between September 2020 and the middle of January 2021, during which D614G variants without many other notable mutations were dominant; the “2nd wave”, between mid-January 2021 and June 2021 was dominated by the B.1.1.7/Alpha variant; the “third wave”, dominated by the B.1.617.2/Delta variant, began in July 2021.

outcomes of suspected reinfections up to December 9th 2021. We classified cases as suspected reinfections if ≥ 90 days have passed between testing positive on at least two different occasions.

After largely successfully escaping the first global wave of infections in the first half of 2020, Bulgaria experienced three major waves of COVID-19, in October-December 2020, in February-April 2021, and in the later months of 2021, of roughly equal magnitude (Figure 1A). Under this criterion, the eligible population to be considered for potential reinfection was $\sim 200,000$ individuals after the first major wave, doubling to $\geq 400,000$ after the second (Figure 1B). These waves were driven by different variants of the SARS-CoV-2 virus. The first was dominated by B.1 lineages antigenically similar to the ancestral strain. The second consisted almost entirely of the Alpha (B.1.1.7) variant^{189,190}, while in the third the globally dominant by then Delta (B.1.6.17.2/AY.*) variant¹⁹¹ constituted almost all cases (Figure 1C). We have defined for the purposes of our analyses the dividing lines between these waves as mid-January 2021 and beginning of June 2021.

In total, we identified 4,106 cases of individuals infected more than once, including 31 cases of people infected three times and one case of a quadruple infection.

The number of reinfections in the first major wave in

late 2020 was small, peaking at ≤ 100 such case weekly, reflecting the low incidence of COVID-19 earlier that year (Figure 1C). A larger though still relatively small number of reinfections were observed during the Alpha wave in the first half of 2021. The bulk of reinfections came during the Delta wave in the second half of the year, peaking at 755 a week at the end of October 2021. During the Delta wave reinfections constituted $\sim 2.3\%$ of cases in Bulgaria. Taking into account the number of eligible for reinfection individuals, during the months of October and November protection from reinfection is estimated to have stood at $\sim 81\%$ (95% CI¹⁹², 63% to 100%).

We then examined the time between primary and subsequent infections. We observe a peak at approximately a year from the initial infection, but the distribution is highly dispersed and a large number of reinfections are observed all throughout the interval from 90 to 360 days (Figure 2A). These numbers correspond primarily to a cohort of people who were infected in the first wave and then reinfected in the Delta wave ($n = 1,674$), and another group of people infected during the Alpha wave and then reinfected during the Delta wave ($n = 1,435$).




Figure 3: Clinical severity of SARS-CoV-2 reinfections in previously infected individuals in Bulgaria . (A) Percentage of hospitalizations among cases in primary infections, breakthrough infections (infections in vaccinated individuals), reinfections (divided into reinfections in the unvaccinated and breakthrough reinfections) (B) Percentage of deaths among cases in primary infections, breakthrough infections (infections in vaccinated individuals), reinfections (divided into reinfections in the unvaccinated and breakthrough reinfections). Binomial proportion confidence intervals were estimated using the Clopper-Pearson exact binomial interval method.

Clinical severity of reinfections

Next we analyzed the clinical outcomes of reinfections and compared it to outcomes from primary infections and from infections in vaccinated individuals (“breakthrough infections”).

Among the 4,106 reinfections, 413 were also “breakthrough reinfections”, i.e. the reinfection occurred after a vaccination course was completed. We divided the reinfection cases into separate unvaccinated and breakthrough reinfection categories.

A total of 84 fatalities were recorded within the reinfection cases, one of them within the set of 31 individu-

als with three infections. This corresponds to an apparent lower case fatality rate (CFR) than the total CFR in Bulgaria for the studied period (~2% compared to ~4.2). In terms of hospitalizations, for the 4,106 reinfected individuals, 705 hospitalizations were recorded for the second infections (a rate of 17.7%); this compares to 8,177 hospitalizations out of 49,170 vaccinated subjects (16.6%) and 109,108 hospitalizations out 332,510 total primary infections (32.8%). However, such comparisons based on total numbers are confounded by the fact the populations are not age matched.

We therefore divided cases in all four categories into age groups and compared the rates of hospitalizations and fa-

talities in each (Figure 3). This analysis reveals a moderately reduced rate of hospitalizations between primary infections and reinfections across all age groups (we observe 40% reduction of risk in the 20-60 age group and 31% in the 60+ age group for the unvaccinated reinfected, and 60% and 40% for the vaccinated reinfected, respectively), and a less pronounced of risk of death (38% reduction in the 20-60 age group and 25% in the 60+ age group for the unvaccinated reinfected; note that total numbers were too small for breakthrough reinfections for an accurate estimate). For comparison the severity of breakthrough infections was more strongly reduced compared to primary infections in the unvaccinated (60%/70% risk reductions for hospitalization/death in the 20-60 age group and 49%/66% in the 60+), although that effect diminished in the higher age groups (consistent with previous findings of lower vaccine efficacy in the elderly^{193–195}).

Conclusions

In this study we evaluated the rate of incidence and the clinical outcomes of SARS-CoV-2 reinfections during the first three waves of the COVID-19 pandemic in Bulgaria, and compared them to primary infections and breakthrough infections in vaccinated individuals. The bulk of reinfections happened during the Delta variant-driven wave, with prior infection providing protection from reinfection $\sim 80\%$. Clinical severity was somewhat reduced relative to primary infections, but to a lesser extent than the observed reduction in severity in breakthrough infections in the vaccinated. A possible limitation of our study is the possibility that in some individuals the disease may have passed with mild symptoms or asymptomatic and so not all cases have been properly diagnosed and registered in the national system, leading to some bias towards documenting symptomatic infections. Results regarding the relative severity of reinfections in the literature have ranged from finding no difference in the severity of reinfections and primary infection to finding considerable (though rarely very high) degree of reduction from severe outcomes¹⁷¹; our results also fit within this range of estimates.

Notes

Competing Interests

The authors declare no competing interests.

Acknowledgments and Funding

The authors would like to acknowledge the help of the Bulgarian Ministry of Health and Information Services for providing us with raw data about reinfections, demographics and vaccination status.

References

1. Wang C, Horby PW, Hayden FG, Gao GF. 2020. A novel coronavirus outbreak of global health concern. *Lancet* **395**(10223):470–473.
2. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL. 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* **579**(7798):270–273.
3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* **395**(10223):497–506.
4. McIntosh K, Becker WB, Chanock RM. 1967. Growth in suckling-mouse brain of “IBV-like” viruses from patients with upper respiratory tract disease. *Proc Natl Acad Sci U S A* **58**(6):2268–2273
5. McIntosh K, Dees JH, Becker WB, Kapikian AZ, Chanock RM. 1967. Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease. *Proc Natl Acad Sci USA* **57**:933–940.
6. Hamre D, Procknow JJ. 1966. A new virus isolated from the human respiratory tract. *Proc Soc Exp Biol Med* **121**(1):190–193
7. Fouchier RA, Hartwig NG, Bestebroer TM, Niemeyer B, de Jong JC, Simon JH, Osterhaus AD.. 2004. A previously undescribed coronavirus associated with respiratory disease in humans. *Proc Natl Acad Sci U S A* **101**(16):6212–6216
8. Pyrc K, Jebbink MF, Berkhout B, van der Hoek L. 2004. Genome structure and transcriptional regulation of human coronavirus NL63. *Virology* **1**:7
9. Woo PC, Lau SK, Chu CM, Chan KH, Tsoi HW, Huang Y, Wong BH, Poon RW, Cai JJ, Luk WK, Poon LL, Wong SS, Guan Y, Peiris JS, Yuen KY. 2005. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. *J Virol* **79**(2):884–895
10. Lau SK, Woo PC, Yip CC, Tse H, Tsoi HW, Cheng VC, Lee P, Tang BS, Cheung CH, Lee RA, So LY, Lau YL, Chan KH, Yuen KY. 2006. Coronavirus HKU1 and other coronavirus infections in Hong Kong. *J Clin Microbiol* **44**(6):2063–2071
11. Vabret A, Dina J, Gouarin S, Petitjean J, Corbet S, Freymuth F. 2006. Detection of the new human coronavirus HKU1: a report of 6 cases. *Clin Infect Dis* **42**(5):634–639
12. Wat D. 2004. The common cold: a review of the literature. *Eur J Intern Med* **15**(2):79–88

13. Mäkelä MJ, Puhakka T, Ruuskanen O, Leinonen M, Saikku P, Kimpimäki M, Blomqvist S, Hyypiä T, Arstila P. 1998. Viruses and bacteria in the etiology of the common cold. *J Clin Microbiol* **36**(2):539–542.
14. Larson HE, Reed SE, Tyrrell DA. 1980. Isolation of rhinoviruses and coronaviruses from 38 colds in adults. *J Med Virol* **5**(3):221–29
15. Nicholson KG, Kent J, Hammersley V, Cancio E. 1997. Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective, population based study of disease burden. *BMJ* **315**(7115):1060–1064
16. Yewdell JW. 2021. Individuals cannot rely on COVID-19 herd immunity: Durable immunity to viral disease is limited to viruses with obligate viremic spread. *PLoS Pathog* **17**(4):e100950
17. Callow KA, Parry HF, Sergeant M, Tyrrell DA. 1990. The time course of the immune response to experimental coronavirus infection of man. *Epidemiol Infect* **105**:435–446.
18. Monto AS. Medical reviews: coronaviruses. *Yale J Biol Med* **47**:234–251.
19. Kahn JS, McIntosh K. 2005. History and recent advances in coronavirus discovery. *Pediatr Infect Dis J* **24**(11 Suppl):S223–227.
20. Mahase E. 2020. Covid-19: WHO and South Korea investigate reconfirmed cases. *BMJ* **369**:m1498
21. de Vriese J. 2020. Reinfections, still rare, provide clues on immunity. *Science* **370**(6519):895–897.
22. Arafkas M, Khosrawipour T, Kochbach P, Zielinski K, Schubert J, Mikolajczyk A, Celinska M, Khosrawipour V. 2021. Current meta-analysis does not support the possibility of COVID-19 reinfections. *J Med Virol* **93**(3):1599–1604.
23. Ledford H. 2020. Coronavirus reinfections: three questions scientists are asking. *Nature* **585**(7824):168–169.
24. Jabbari P, Rezaei N. 2020. With Risk of Reinfection, Is COVID-19 Here to Stay? *Disaster Med Public Health Prep* **14**(4):e33
25. Duggan NM, Ludy SM, Shannon BC, Reisner AT, Wilcox SR. 2021. Is novel coronavirus 2019 reinfection possible? Interpreting dynamic SARS-CoV-2 test results. *Am J Emerg Med* **39**:256.e1-256.e3.
26. York A. 2020. Can COVID-19 strike twice? *Nat Rev Microbiol* **18**(9):477.
27. Law SK, Leung AWN, Xu C. 2020. Is reinfection possible after recovery from COVID-19? *Hong Kong Med J* **26**(3):264–265.
28. Tang CY, Wang Y, McElroy JA, Li T, Hammer R, Ritter D, Lidl GM, Webby R, Hang J, Wan XF. 2021. Reinfection with two genetically distinct SARS-CoV-2 viruses within 19 days. *J Med Virol* **93**(10):5700–5703.
29. Lee JS, Kim SY, Kim TS, Hong KH, Ryoo NH, Lee J, Park JH, Cho SI, Kim MJ, Kim YG, Kim B, Shin HS, Oh HS, Seo MS, Gwon TR, Kim Y, Park JS, Chin BS, Park WB, Park SS, Seong MW. 2020. Evidence of Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection After Recovery from Mild Coronavirus Disease 2019. *Clin Infect Dis* ciaa1421.
30. Mulder M, van der Vegt DSJM, Oude Munnink BB, GeurtsvanKessel CH, van de Bovenkamp J, Sikkema RS, Jacobs EMG, Koopmans MPG, Wegdam-Blans MCA. 2020. Reinfection of SARS-CoV-2 in an immunocompromised patient: a case report. *Clin Infect Dis* ciaa1538
31. To KK, Hung IF, Ip JD, Chu AW, Chan WM, Tam AR, Fong CH, Yuan S, Tsoi HW, Ng AC, Lee LL, Wan P, Tso E, To WK, Tsang D, Chan KH, Huang JD, Kok KH, Cheng VC, Yuen KY. 2020. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. *Clin Infect Dis* ciaa1275
32. Larson D, Brodniak SL, Voegtly LJ, Cer RZ, Glang LA, Malagon FJ, Long KA, Potocki R, Smith DR, Lanteri C, Burgess T, Bishop-Lilly KA. 2020. A Case of Early Re-infection with SARS-CoV-2. *Clin Infect Dis* ciaa1436
33. Goldman JD, Wang K, Roltgen K, Nielsen SCA, Roach JC, Naccache SN, Yang F, Wirz OF, Yost KE, Lee JY, Chun K, Wrin T, Petropoulos CJ, Lee I, Fallen S, Manner PM, Wallick JA, Algren HA, Murray KM, Su Y, Hadlock J, Jeharajah J, Berrington WR, Pappas GP, Nyatsatsang ST, Greninger AL, Satpathy AT, Pauk JS, Boyd SD, Heath JR. 2020. Reinfection with SARS-CoV-2 and Failure of Humoral Immunity: a case report. *medRxiv* 2020.09.22.20192443
34. Tillett RL, Sevinsky JR, Hartley PD, Kerwin H, Crawford N, Gorzalski A, Laverdure C, Verma SC, Rossetto CC, Jackson D, Farrell MJ, Van Hooser S, Pandori M. 2021. Genomic evidence for reinfection with SARS-CoV-2: a case study. *Lancet Infect Dis* **21**(1):52–58.
35. Prado-Vivar B, Becerra-Wong M, Guadalupe JJ, Márquez S, Gutierrez B, Rojas-Silva P, Grunauer M, Trueba G, Barragán V, Cadenas P. 2021. A case of SARS-CoV-2 reinfection in Ecuador. *Lancet Infect Dis* **21**(6):e142.
36. Sevillano G, Ortega-Paredes D, Loaiza K, Zurita-Salinas C, Zurita J. 2021. Evidence of SARS-CoV-2 reinfection within the same clade in Ecuador: A case study. *Int J Infect Dis* **108**:53–56.
37. Gupta V, Bhojar RC, Jain A, Srivastava S, Upadhayay R, Imran M, Jolly B, Divakar MK, Sharma D, Sehgal P, Ranjan G, Gupta R, Scaria V, Sivasubbu S. 2020. Asymptomatic reinfection in two healthcare workers from India with genetically distinct SARS-CoV-2. *Clin Infect Dis* ciaa1451
38. Shastri J, Parikh S, Agrawal S, Chatterjee N, Pathak M, Chaudhary S, Sharma C, Kanakan A, A V, Srinivasa Vasudevan J, Maurya R, Fatihi S, Thukral L, Agrawal A, Pinto L, Pandey R, Sunil S. 2021. Clinical, Serological, Whole Genome Sequence Analyses to

- Confirm SARS-CoV-2 Reinfection in Patients From Mumbai, India. *Front Med (Lausanne)* **8**:631769
39. Resende PC, Bezerra JF, Teixeira Vasconcelos RH, Arantes I, Appolinario L, Mendonça AC, Paixão AC, Duarte AC, Silva T, Rocha AS, Lima ABM, Pauvolid-Corrêa A, Motta FC, Teixeira DLF, de Oliveira Carneiro TF, Neto FPF, Herbster ID, Leite AB, Riediger IN, do Carmo Debur M, Naveca FG, Almeida W, Livorati M, Bello G, Siqueira MM. 2021. Severe Acute Respiratory Syndrome Coronavirus 2 P.2 Lineage Associated with Reinfection Case, Brazil, June-October 2020. *Emerg Infect Dis* **27**(7):1789–1794.
 40. Nonaka CKV, Franco MM, Gräf T, de Lorenzo Barcia CA, de Ávila Mendonça RN, de Sousa KAF, Neiva LMC, Fosenca V, Mendes AVA, de Aguiar RS, Giovanetti M, de Freitas Souza BS. 2021. Genomic Evidence of SARS-CoV-2 Reinfection Involving E484K Spike Mutation, Brazil. *Emerg Infect Dis* **27**(5):1522–1524.
 41. Mahajan NN, Gajbhiye RK, Lokhande PD, Bahirat S, Modi D, Mathe AM, Bharmal R, Rath S, Mohite SC, Tilve A. 2021. Clinical Presentation of Cases with SARS-CoV-2 Reinfection/ Reactivation. *J Assoc Physicians India* **69**(1):16–18.
 42. Garvey MI, Casey AL, Wilkinson MAC, Ratcliffe L, McMurray C, Stockton J, Holden E, Osman H, Loman NJ. 2021. Details of SARS-CoV-2 reinfections at a major UK tertiary centre. *J Infect* **82**(6):e29–e30.
 43. Harrington D, Kele B, Pereira S, Couto-Parada X, Riddell A, Forbes S, Dobbie H, Cutino-Moguel T. 2021. Confirmed Reinfection with SARS-CoV-2 Variant VOC-202012/01. *Clin Infect Dis* ciab014
 44. Zucman N, Uhel F, Descamps D, Roux D, Ricard JD. 2021. Severe reinfection with South African SARS-CoV-2 variant 501Y.V2: A case report. *Clin Infect Dis* ciab129
 45. Ramírez JD, Muñoz M, Ballesteros N, Patiño LH, Castañeda S, Rincón CA, Mendez C, Oliveros C, Perez J, Márquez EK, Ortiz FLS, Correa-Cárdenas CA, Duque MC, Paniz-Mondolfi A. 2021. Phylogenomic Evidence of Reinfection and Persistence of SARS-CoV-2: First Report from Colombia. *Vaccines (Basel)* **9**(3):282.
 46. Van Elslande J, Vermeersch P, Vandervoort K, Wawina-Bokalanga T, Vanmechelen B, Wollants E, Laenen L, André E, Van Ranst M, Lagrou K, Maes P. 2021. Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection by a Phylogenetically Distinct Strain. *Clin Infect Dis* **73**(2):354–356.
 47. Tomassini S, Kotecha D, Bird PW, Folwell A, Biju S, Tang JW. 2021. Setting the criteria for SARS-CoV-2 reinfection - six possible cases. *J Infect* **82**(2):282–327.
 48. Hoang VT, Dao TL, Gautret P. 2020. Recurrence of positive SARS-CoV-2 in patients recovered from COVID-19. *J Med Virol* **92**(11):2366–2367.
 49. Bongiovanni M. 2021. COVID-19 reinfection in a healthcare worker. *J Med Virol* **93**(7):4058–4059.
 50. Salzer HJF, Neuböck M, Heldt S, Haug I, Paar C, Lamprecht B. 2021. Emerging COVID-19 reinfection four months after primary SARS-CoV-2 infection. *Wien Med Wochenschr* 1–3. doi: 10.1007/s10354-021-00813-1
 51. Sicsic I Jr, Chacon AR, Zaw M, Ascher K, Abreu A, Chediak A. 2021. A case of SARS-CoV-2 reinfection in a patient with obstructive sleep apnea managed with telemedicine. *BMJ Case Rep* **14**(2):e240496
 52. Salcin S, Fontem F. 2021. Recurrent SARS-CoV-2 infection resulting in acute respiratory distress syndrome and development of pulmonary hypertension: A case report. *Respir Med Case Rep* **33**:101314.
 53. Selhorst P, Van Ierssel S, Michiels J, Maria J, Bartholomeeusen K, Dirinck E, Vandamme S, Jansens H, Ariën KK. 2020. Symptomatic SARS-CoV-2 reinfection of a health care worker in a Belgian nosocomial outbreak despite primary neutralizing antibody response. *Clin Infect Dis* ciaa1850.
 54. Scarpati G, Piazza O, Pagliano P, Rizzo F. 2021. COVID-19: a confirmed case of reinfection in a nurse. *BMJ Case Rep* **14**(7):e244507
 55. Garg J, Agarwal J, Das A, Sen M. 2021. Recurrent COVID-19 infection in a health care worker: a case report. *J Med Case Rep* **15**(1):363
 56. Goes LR, Siqueira JD, Garrido MM, Alves BM, Pereira ACPM, Cicala C, Arthos J, Viola JPB, Soares MA; INCA COVID-19 Task Force. 2021. New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil. *Infect Genet Evol* **94**:104998
 57. Ahmadian S, Fathizadeh H, Shabestari Khiabani S, Asgharzadeh M, Kafil HS. 2021. COVID-19 reinfection in a healthcare worker after exposure with high dose of virus: A case report. *Clin Case Rep* **9**(6):e04257.
 58. Amorim MR, Souza WM, Barros ACG Jr, Toledo-Teixeira DA, Dos-Santos KB, Simeoni CL, Parise PL, Vieira A, Forato J, Claro IM, Mofatto LS, Barbosa PP, Brunetti NS, Franca ESS, Pedroso GA, Carvalho BFN, Zaccariotto TR, Krywacz KCS, Vieira AS, Mori MA, Farias AS, Pavan MHP, Bachur LF, Cardoso LGO, Spilki FR, Sabino EC, Faria NR, Santos MNN, Angerami R, Leme PAF, Schreiber A, Moretti ML, Granja F, Proença-Modena JL. 2021. Respiratory Viral Shedding in Healthcare Workers Reinfected with SARS-CoV-2, Brazil, 2020. *Emerg Infect Dis* **27**(6):1737–1740.
 59. Bongiovanni M, Marra AM, Bini F, Bodini BD, Carlo DD, Giuliani G. 2021. COVID-19 reinfection in healthcare workers: A case series. *J Infect* **82**(6):e4–e5.
 60. Salehi-Vaziri M, Omrani MD, Pouriayevali MH, Fotouhi F, Banifazl M, Farahmand B, Sadat Larijani M, Ahmadi Z, Fereydouni Z, Tavakoli M, Jalali T, Ramezani A. 2021. SARS-CoV-2 presented moder-

- ately during two episodes of the infection with lack of antibody responses. *Virus Res* **299**:198421.
61. Bonifácio LP, Pereira APS, Araújo DCAE, Balbão VDMP, Fonseca BALD, Passos ADC, Bellissimo-Rodrigues F. 2020. Are SARS-CoV-2 reinfection and Covid-19 recurrence possible? a case report from Brazil. *Rev Soc Bras Med Trop* **53**:e20200619
 62. Silva MSD, Demoliner M, Hansen AW, Gularte JS, Silveira F, Heldt FH, Filippi M, Pereira VMAG, Silva FPD, Mallmann L, Fink P, Silva LLD, Weber MN, Almeida PR, Fleck JD, Spilki FR. 2021. Early detection of SARS-CoV-2 P.1 variant in Southern Brazil and reinfection of the same patient by P.2. *Rev Inst Med Trop Sao Paulo* **63**:e58
 63. Yu ALF, Liphaut BL, Ferreira PM, Tanamachi AT, Masuda ET, Trevisan CM, Lucas PCC, Bugno A, Carvalhanas TRMP. 2021. SARS-CoV-2 reinfection: report of two cases in Southeast Brazil. *Rev Inst Med Trop Sao Paulo* **63**:e50.
 64. Romano CM, Felix AC, Paula AV, Jesus JG, Andrade PS, Cândido D, Oliveira FM, Ribeiro AC, Silva FCD, Inemami M, Costa AA, Leal COD, Figueiredo WM, Pannuti CS, Souza WM, Faria NR, Sabino EC. 2021. SARS-CoV-2 reinfection caused by the P.1 lineage in Araraquara city, Sao Paulo State, Brazil. *Rev Inst Med Trop Sao Paulo* **63**:e36.
 65. West J, Everden S, Nikitas N. 2021. A case of COVID-19 reinfection in the UK. *Clin Med (Lond)* **21**(1):e52–e53.
 66. Sharma R, Sardar S, Mohammad Arshad A, Ata F, Zara S, Munir W. 2020. A Patient with Asymptomatic SARS-CoV-2 Infection Who Presented 86 Days Later with COVID-19 Pneumonia Possibly Due to Reinfection with SARS-CoV-2. *Am J Case Rep* **21**:e927154
 67. Ozaras R, Ozdogru I, Yilmaz AA. 2020. Coronavirus disease 2019 re-infection: first report from Turkey. *New Microbes New Infect* **38**:100774.
 68. Colson P, Finaud M, Levy N, Lagier JC, Raoult D. 2021. Evidence of SARS-CoV-2 re-infection with a different genotype. *J Infect* **82**(4):84–123.
 69. Selvaraj V, Herman K, Dapaah-Afriyie K. 2020. Severe, Symptomatic Reinfection in a Patient with COVID-19. *R I Med J (2013)* **103**(10):24–26.
 70. AlFehaidi A, Ahmad SA, Hamed E. 2021. SARS-CoV-2 re-infection: a case report from Qatar. *J Infect* **82**(3):414–451.
 71. de Brito CAA, Lima PMA, de Brito MCM, de Oliveira DB. 2020. Second Episode of COVID-19 in Health Professionals: Report of Two Cases. *Int Med Case Rep J* **13**:471-475
 72. Mulder M, van der Vegt DSJM, Oude Munnink BB, GeurtsvanKessel CH, van de Bovenkamp J, Sikkema RS, Jacobs EMG, Koopmans MPG, Wegdam-Blans MCA. 2020. Reinfection of SARS-CoV-2 in an immunocompromised patient: a case report. *Clin Infect Dis* **71**:e1538.
 73. Hanif M, Haider MA, Ali MJ, Naz S, Sundas F. 2020. Reinfection of COVID-19 in Pakistan: A First Case Report. *Cureus* **12**(10):e11176.
 74. Ferrante L, Livas S, Steinmetz WA, Almeida ACL, Leão J, Vassão RC, Tupinambás U, Fearnside PM, Duczmal LH. 2021. The First Case of Immunity Loss and SARS-CoV-2 Reinfection by the Same Virus Lineage in Amazonia. *J Racial Ethn Health Disparities* **8**(4):821–823
 75. Arteaga-Livias K, Panduro-Correa V, Pinzas-Acosta K, Perez-Abad L, Pecho-Silva S, Espinoza-Sánchez F, Dámaso-Mata B, Rodriguez-Morales AJ. 2021. COVID-19 reinfection? A suspected case in a Peruvian patient. *Travel Med Infect Dis* **39**:101947
 76. Novoa W, Miller H, Mattar S, Faccini-Martínez A, Rivero R, Serrano-Coll H. 2021. A first probable case of SARS-CoV-2 reinfection in Colombia. *Ann Clin Microbiol Antimicrob* **20**(1):7
 77. Alzedam A, Bengblya AM, Zeglam MJ, Benmasoud ET, Bennji SM. 2021. A case of COVID-19 re-infection in Libya. *Afr J Thorac Crit Care Med* **27**(2):10.7196/AJTCCM.2021.v27i2.131
 78. Camargo CH, Goncalves CR, Pagnoca EVRG, Campos KR, Montanha JOM, Flores MNP, Soares MMCN, Binhardi FMT, Ferreira PM, Yu ALF, Carvalhanas TRMP, Abbud A, Bugno A, Sacchi CT. 2021. SARS-CoV-2 reinfection in a healthcare professional in inner Sao Paulo during the first wave of COVID-19 in Brazil. *Diagn Microbiol Infect Dis* **101**(4):115516
 79. Díaz Y, Ortiz A, Weeden A, Castillo D, González C, Moreno B, Martínez-Montero M, Castillo M, Vasquez G, Sáenz L, Franco D, Pitti Y, Chavarria O, Gondola J, Moreno AM, Ábrego L, Beltrán D, Guerra I, Chang J, Chaverra Z, Guerrero I, Valoy A, Gaitán M, Araúz D, Morán E, Chen-Germán M, Valdespino E, Rodríguez R, Corrales R, Chen-Camaño R, Pascale JM, Martínez AA, López-Vergés S; Gorgas COVID19 Team. 2021. SARS-CoV-2 reinfection with a virus harboring mutation in the Spike and the Nucleocapsid proteins in Panama. *Int J Infect Dis* **108**:588–591.
 80. Aguilar-Shea AL, Gutiérrez-Martín-Arroyo J, Vacas-Córdoba M, Gallardo-Mayo C. 2021. Reinfection by SARS-CoV-2: The first one in a family reported in Spain. *Med Clin (Barc)* **S0025-7753(21)00250-5**
 81. Rodríguez-Espinosa D, Broseta Monzó JJ, Casals Q, Piñeiro GJ, Rodas L, Vera M, Maduell F. 2021. Fatal SARS-CoV-2 reinfection in an immunosuppressed patient on hemodialysis. *J Nephrol* **34**(4):1041–1043.
 82. Sanyang B, Kanteh A, Usuf E, Nadjm B, Jarju S, Bah A, Bojang A, Grey-Johnson M, Jones JC, Gai A, Sarr C, Sillah F, Wariri O, Oko F, Cerami C, Forrest K, Sey AP, Jallow H, Nwakanma D, Sesay AK, D'Alessandro U, Roca A. 2021. COVID-19 reinfections in The Gambia by phylogenetically distinct SARS-CoV-2 variants—first two confirmed events in west Africa. *Lancet Glob Health* **9**(7):e905–e907

83. Loconsole D, Sallustio A, Accogli M, Centrone F, Casulli D, Madaro A, Tedeschi E, Parisi A, Chironna M. 2021. Symptomatic SARS-CoV-2 Reinfection in a Healthy Healthcare Worker in Italy Confirmed by Whole-Genome Sequencing. *Viruses* **13**(5):899
84. Garduño-Orbe B, Sánchez-Rebolledo JM, Cortés-Rafael M, García-Jiménez Y, Perez-Ortiz M, Mendiola-Pastrana IR, López-Ortiz E, López-Ortiz G. 2021. SARS-CoV-2 Reinfection among Healthcare Workers in Mexico: Case Report and Literature Review. *Medicina (Kaunas)* **57**(5):442
85. Vora T, Vora P, Vora F, Sharma K, Desai HD. 2021. Symptomatic reinfection with COVID-19: A first from Western India. *J Family Med Prim Care* **10**(3):1496–1498.
86. Sánchez Mollá M, de Gregorio Bernardo C, Ibarra Rizo M, Soriano A. 2021. [Reinfection by SARS-CoV-2 in a socio-sanitary residence. Description of the outbreak]. *Aten Primaria* **53**(8):102100.
87. Fageeh H, Alshehri A, Fageeh H, Bizzoca ME, Lo Muzio L, Quadri MFA. 2021. Re-infection of SARS-CoV-2: A case in a young dental healthcare worker. *J Infect Public Health* **14**(6):685–688.
88. Novazzi F, Baj A, Genoni A, Spezia PG, Colombo A, Cassani G, Zago C, Pasciuta R, Della Gasperina D, Ageno W, Severgnini P, Dentali F, Focosi D, Maggi F. 2021. SARS-CoV-2 B.1.1.7 reinfection after previous COVID-19 in two immunocompetent Italian patients. *J Med Virol* **93**(9):5648–5649.
89. Letizia AG, Smith DR, Ge Y, Ramos I, Sealfon RSG, Goforth C, Gonzalez-Reiche AS, Vangeti S, Weir DL, Alshammery H, Chen HW, George MC, Soares-Schanoski A, Lizewski RA, Lizewski SE, Marayag J, Miller CM, Nunez E, Porter CK, Ana ES, Schilling M, Sugiharto VA, Sun P, Termini M, van de Guchte A, Troyanskaya OG, van Bakel H, Sealfon SC. 2021. Viable virus shedding during SARS-CoV-2 reinfection. *Lancet Respir Med* **9**(7):e56–e57
90. Staub T, Arendt V, Lasso de la Vega EC, Braquet P, Michaux C, Kohnen M, Tsobo C, Abdelrahman T, Wienecke-Baldacchino A, Francois JH. 2021. Case series of four re-infections with a SARS-CoV-2 B.1.351 variant, Luxembourg, February 2021. *Euro Surveill* **26**(18):2100423.
91. Brehm TT, Pfefferle S, von Possel R, Kobbe R, Nörz D, Schmiedel S, Grundhoff A, Olearo F, Emmerich P, Robitaille A, Günther T, Braun P, Andersen G, Knobloch JK, Addo MM, Lohse AW, Aepfelbacher M, Fischer N, Schulze Zur Wiesch J, Lütgehetmann M. 2021. SARS-CoV-2 Reinfection in a Healthcare Worker Despite the Presence of Detectable Neutralizing Antibodies. *Viruses* **13**(4):661.
92. Konstantinou F, Skrapari I, Baretta E, Bakogiannis N, Papadopoulou AM, Bakoyiannis C. 2021. A Case of SARS-CoV-2 Clinical Relapse after 4 Negative RT-PCR Tests in Greece: Recurrence or Reinfection? *Clin Med Insights Case Rep* **14**:11795476211009813.
93. Shoar S, Khavandi S, Tabibzadeh E, Khavandi S, Naderan M, Shoar N. 2021. Recurrent coronavirus diseases 19 (COVID-19): A different presentation from the first episode. *Clin Case Rep* **9**(4):2149–2152.
94. Rani PR, Imran M, Lakshmi JV, Jolly B, Jain A, Surekha A, Senthivel V, Chandrasekhar P, Divakar MK, Srinivasulu D, Bhojar RC, Vanaja PR, Scaria V, Sivasubbu S. 2021. Symptomatic reinfection of SARS-CoV-2 with spike protein variant N440K associated with immune escape. *J Med Virol* **93**(7):4163–4165.
95. Vánca S, Dembrovszky F, Farkas N, Szakó L, Teutsch B, Bunduc S, Nagy R, Párnicsky A, Eróss B, Péterfi Z, Hegyi P. 2021. Repeated SARS-CoV-2 Positivity: Analysis of 123 Cases. *Viruses* **13**(3):512
96. Das P, Satter SM, Ross AG, Abdullah Z, Nazneen A, Sultana R, Rimi NA, Chowdhury K, Alam R, Parveen S, Rahman MM, Hossain ME, Rahman MZ, Mazumder R, Abdullah A, Rahman M, Banu S, Ahmed T, Clemens JD, Rahman M. 2021. A Case Series Describing the Recurrence of COVID-19 in Patients Who Recovered from Initial Illness in Bangladesh. *Trop Med Infect Dis* **6**(2):41.
97. Fintelman-Rodrigues N, da Silva APD, Dos Santos MC, Saraiva FB, Ferreira MA, Gesto J, Rodrigues DAS, Vale AM, de Azevedo IG, Soares VC, Jiang H, Tan H, Tschoeke DA, Sacramento CQ, Bozza FA, Morel CM, Bozza PT, Souza TML. 2021. Genetic Evidence and Host Immune Response in Persons Reinfected with SARS-CoV-2, Brazil. *Emerg Infect Dis* **27**(5):1446–1453.
98. Teka IA, BenHasan MH, Alkershini AA, Alatresh OK, Abulifa TA, Lembagga HA, Alhudiri IM, Elzagheid A. 2021. Reinfection with SARS-CoV-2: A case report from Libya. *Travel Med Infect Dis* **41**:102040
99. Roy S. 2021. COVID-19 Reinfection in the Face of a Detectable Antibody Titer. *Cureus* **13**(3):e14033.
100. Fernandes AC, Figueiredo R. 2021. SARS-CoV-2 reinfection: a case report from Portugal. *Rev Soc Bras Med Trop* **54**:e0002-2021.
101. Ul-Haq Z, Khan A, Fazid S, Noor F, Yousafzai YM, Sherin A. 2020. First documented reinfection of SARS-CoV-2 in second wave from Pakistan. *J Ayub Med Coll Abbottabad* **32**(Suppl 1)(4):S704-S705.
102. Krishna VN, Ahmad M, Overton ET, Jain G. 2021. Recurrent COVID-19 in Hemodialysis: A Case Report of 2 Possible Re-infections. *Kidney Med* **3**(3):447–450.
103. Leung S, Hossain N. 2021. Recurrence and Recovery of COVID-19 in an Older Adult Patient with Multiple Comorbidities: A Case Report. *Gerontology* **67**(4):445–448.
104. Salehi-Vaziri M, Jalali T, Farahmand B, Fotouhi F, Banifazl M, Pouriayevali MH, Sadat Larijani M, Afzali N, Ramezani A. 2021. Clinical characteristics of SARS-CoV-2 by re-infection vs. reactivation: a

- case series from Iran. *Eur J Clin Microbiol Infect Dis* **40**(8):1713–1719.
105. Romera I, Núñez K, Calizaya M, Baeza I, Molina R, Morillas J. 2021. SARS-CoV-2 reinfection. *Med Intensiva (Engl Ed)* **45**(6):375–376.
 106. Yadav SP, Wadhwa T, Thakkar D, Kapoor R, Rastogi N, Sarma S. 2021. COVID-19 reinfection in two children with cancer. *Pediatr Hematol Oncol* **38**(4):403–405.
 107. Cavanaugh AM, Thoroughman D, Miranda H, Spicer K. 2021. Suspected Recurrent SARS-CoV-2 Infections Among Residents of a Skilled Nursing Facility During a Second COVID-19 Outbreak - Kentucky, July–November 2020. *MMWR Morb Mortal Wkly Rep* **70**(8):273–277.
 108. Vetter P, Cordey S, Schibler M, Vieux L, Despres L, Laubscher F, Andrey DO, Martischang R, Harbarth S, Cuvelier C, Bekliz M, Eckerle I, Siegrist CA, Didierlaurent AM, Eberhardt CS, Meyer B, Kaiser L; Geneva Center for Emerging Viral Diseases. 2021. Clinical, virologic and immunologic features of a mild case of SARS-CoV-2 reinfection. *Clin Microbiol Infect* **27**(5):791.e1–4.
 109. Lee JT, Hesse EM, Paulin HN, Datta D, Katz LS, Talwar A, Chang G, Galang RR, Harcourt JL, Tamin A, Thornburg NJ, Wong KK, Stevens V, Kim K, Tong S, Zhou B, Queen K, Drobeniuc J, Folster JM, Sexton DJ, Ramachandran S, Browne H, Iskander J, Mitruka K. 2021. Clinical and Laboratory Findings in Patients with Potential SARS-CoV-2 Reinfection, May–July 2020. *Clin Infect Dis* ciab148.
 110. Kulkarni O, Narreddy S, Zaveri L, Kalal IG, Tallapaka KB, Sowpati DT. 2021. Evidence of SARS-CoV-2 reinfection without mutations in Spike protein. *Clin Infect Dis* ciab136.
 111. Adrielle Dos Santos L, Filho PGG, Silva AMF, Santos JVG, Santos DS, Aquino MM, de Jesus RM, Almeida MLD, da Silva JS, Altmann DM, Boyton RJ, Alves Dos Santos C, Santos CNO, Alves JC, Santos IL, Magalhães LS, Belitardo EMMA, Rocha DJPG, Almeida JPP, Pacheco LGC, Aguiar ERGR, Campos GS, Sardi SI, Carvalho RH, de Jesus AR, Rezende KF, de Almeida RP. 2021. Recurrent COVID-19 including evidence of reinfection and enhanced severity in thirty Brazilian healthcare workers. *J Infect* **82**(3):399–406.
 112. Inada M, Ishikane M, Terada M, Matsunaga A, Maeda K, Tsuchiya K, Miura K, Sairenji Y, Kinoshita N, Ujiie M, Kutsuna S, Ishizaka Y, Mitsuya H, Ohmagari N. 2021. Asymptomatic COVID-19 re-infection in a Japanese male by elevated half-maximal inhibitory concentration (IC₅₀) of neutralizing antibodies. *J Infect Chemother* **27**(7):1063–1067.
 113. Fonseca V, de Jesus R, Adelino T, Reis AB, de Souza BB, Ribeiro AA, Guimarães NR, Livorati MTFP, Neto DFL, Kato RB, Portela LMO, Dutra LH, Freitas C, de Abreu AL, Filizzola ERM, de Medeiros AC, Iani FCM, Carvalho G, Lourenço J, de Oliveira T, Alcantara LCJ, Giovanetti M. 2021. Genomic evidence of SARS-CoV-2 reinfection case with the emerging B.1.2 variant in Brazil. *J Infect* **83**(2):237–279.
 114. Zhou X, Zhou YN, Ali A, Liang C, Ye Z, Chen X, Zhang Q, Deng L, Sun X, Zhang Q, Luo J, Li W, Zhou K, Cao S, Zhang X, Li XD, Zhang XE, Cui Z, Men D. 2021. Case Report: A Re-Positive Case of SARS-CoV-2 Associated With Glaucoma. *Front Immunol* **12**:70129
 115. Massachi J, Donohue KC, Kelly JD. 2021. Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection Cases Corroborated by Sequencing. *Am J Trop Med Hyg* tpm210365.
 116. Massanella M, Martin-Urda A, Mateu L, Marín T, Aldas I, Riveira-Muñoz E, Kipelainen A, Jiménez-Moyano E, Rodríguez de la Concepción ML, Avila-Nieto C, Trinité B, Pradenas E, Rodon J, Marfil S, Parera M, Carrillo J, Blanco J, Prado JG, Ballana E, Vergara-Alert J, Segalés J, Noguera-Julian M, Masabeu À, Clotet B, Toda MR, Paredes R. 2021. Critical Presentation of a Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection: A Case Report. *Open Forum Infect Dis* **8**(7):ofab329
 117. Alshukairi AN, El-Kafrawy SA, Dada A, Yasir M, Yamani AH, Saeedi MF, Aljohaney A, AlJohani NI, Bahauddeen HA, Alam I, Gojobori T, Radovanovic A, Alandijany TA, Othman NA, Alsubhi TL, Hassan AM, Tolah AM, Al-Tawfiq JA, Zumla A, Azhar EI. 2021. Re-infection with a different SARS-CoV-2 clade and prolonged viral shedding in a hematopoietic stem cell transplantation patient. *Int J Infect Dis* **110**:267–271.
 118. Bader N, Khattab M, Farah F. 2021. Severe reinfection with severe acute respiratory syndrome coronavirus 2 in a nursing home resident: a case report. *J Med Case Rep* **15**(1):392.
 119. Awada H, Nassereldine H, Hajj Ali A. 2021. Severe acute respiratory syndrome coronavirus 2 reinfection in a coronavirus disease 2019 recovered young adult: a case report. *J Med Case Rep* **15**(1):382
 120. Zanferrari C, Fanucchi S, Sollazzo MT, Ranieri M, Volterra D, Valvassori L. 2021. Focal Cerebral Arteriopathy in a Young Adult Following SARS-CoV2 Reinfection. *J Stroke Cerebrovasc Dis* **30**(9):105944.
 121. Zhang N, Chen X, Jia W, Jin T, Xiao S, Chen W, Hang J, Ou C, Lei H, Qian H, Su B, Li J, Liu D, Zhang W, Xue P, Liu J, Weschler LB, Xie J, Li Y, Kang M. 2021. Evidence for lack of transmission by close contact and surface touch in a restaurant outbreak of COVID-19. *J Infect* **83**(2):207–216.
 122. Naveca FG, Nascimento VA, Nascimento F, Ogrzewalska M, Pauvolid-Corrêa A, Araujo MF, Arantes I, Batista ÉLR, Magalhães ALÁ, Vinhal F, Mattos TP, Riediger I, do Carmo Debur M, Grinsztejn B, Veloso VG, Brasil P, Rodrigues RR, Rovaris DB, Fer-

- nandes SB, Fernandes C, Santos JHA, Abdalla LF, Costa-Filho R, Silva M, Souza V, Costa AA, Mejía M, Brandão MJ, Goncalves LF, Silva GA, de Jesus MS, Pessoa K, de Lima Guerra Corado A, Duarte DCG, Machado AB, de Azevedo Zukeram K, Valente N, Lopes RS, Pereira EC, Appolinario LR, Rocha AS, Tort LFL, Sekizuka T, Itokawa K, Hashino M, Kuroda M, Wallau GL, Delatorre E, Gräf T, Siqueira MM, Bello G, Resende PC. 2021. A case series of SARS-CoV-2 reinfections caused by the variant of concern Gamma in Brazil. *medRxiv* 2021.11.29.21266109
123. Hasanzadeh S, Shariatmaghani SS, Vakilian A, Javan A, Rahmani M, Ganjloo S, Jangi M, Amel Jamehdar S. 2021. Case series: Reinfection of recovered SARS CoV-2 patients for the third time. *Clin Case Rep* **9**(10):e04936
 124. Pulliam JRC, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome MJ, Dushoff J, Mlisana K, Moultrie H. 2021. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa. *medRxiv* 2021.11.11.21266068
 125. Vitale J, Mumoli N, Clerici P, De Paschale M, Evangelista I, Cei M, Mazzone A. 2021. Assessment of SARS-CoV-2 Reinfection 1 Year After Primary Infection in a Population in Lombardy, Italy. *JAMA Intern Med* e212959
 126. Babiker A, Marvil CE, Waggoner JJ, Collins MH, Piantadosi A. 2020. The importance and challenges of identifying SARS-CoV-2 reinfections. *J Clin Microbiol* **59**(4):e02769–20.
 127. Boyton RJ, Altmann DM. 2021. Risk of SARS-CoV-2 reinfection after natural infection. *Lancet* **397**(10280):1161–1163.
 128. Hansen CH, Michlmayr D, Gubbels SM, Mølbak K, Ethelberg S. 2021. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. *Lancet* **397**(10280):1204–1212.
 129. Gousseff M, Penot P, Gallay L, Batisse D, Benech N, Bouiller K, Collarino R, Conrad A, Slama D, Joseph C, Lemaignen A, Lescure FX, Levy B, Mahevas M, Pozzetto B, Vignier N, Wyplosz B, Salmon D, Goehring F, Botelho-Nevers E; in behalf of the COCOREC study group. 2020. Clinical recurrences of COVID-19 symptoms after recovery: Viral relapse, reinfection or inflammatory rebound? *J Infect* **81**(5):816–846.
 130. Lawandi A, Warner S, Sun J, Demirkale CY, Danner RL, Klompas M, Gundlapalli A, Datta D, Harris AM, Morris SB, Natarajan P, Kadri SS. 2021. Suspected SARS-CoV-2 Reinfections: Incidence, Predictors, and Healthcare Use among Patients at 238 U.S. Healthcare Facilities, June 1, 2020- February 28, 2021. *Clin Infect Dis* ciab671
 131. Iwasaki A. 2020. What reinfections mean for COVID-19. *Lancet Infect Dis* **2**(20):19–20.
 132. Leidi A, Koegler F, Dumont R, Dubos R, Zaballa ME, Piumatti G, Coen M, Berner A, Darbellay Farhoumand P, Vetter P, Vuilleumier N, Kaiser L, Courvoisier D, Azman AS, Guessous I, Stringhini S; SEROCOv-POP study group. 2021. Risk of reinfection after seroconversion to SARS-CoV-2: A population-based propensity-score matched cohort study. *Clin Infect Dis* ciab495
 133. Hall VJ, Foulkes S, Charlett A, Atti A, Monk EJM, Simmons R, Wellington E, Cole MJ, Saei A, Oguti B, Munro K, Wallace S, Kirwan PD, Shrotri M, Vusirikala A, Rokadiya S, Kall M, Zambon M, Ramsay M, Brooks T, Brown CS, Chand MA, Hopkins S; SIREN Study Group. 2021. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). *Lancet* **397**(10283):1459–1469.
 134. Abu-Raddad LJ, Chemaitelly H, Malek JA, Ahmed AA, Mohamoud YA, Younuskunju S, Ayoub HH, Al Kanaani Z, Al Khal A, Al Kuwari E, Butt AA, Coyle P, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Rahim HFA, Yassine HM, Al Kuwari MG, Al Romaihi HE, Al-Thani MH, Bertollini R. 2020. Assessment of the risk of SARS-CoV-2 reinfection in an intense re-exposure setting. *Clin Infect Dis* ciaa1846
 135. Ghorbani SS, Taherpour N, Bayat S, Ghajari H, Mohseni P, Hashemi Nazari SS. 2021. Epidemiologic characteristics of cases with re-infection, recurrence and hospital readmission due to COVID-19: a systematic review and meta-analysis. *J Med Virol* doi: 10.1002/jmv.27281
 136. Santiago-Espinosa O, Prieto-Torres ME, Cabrera-Gaytán DA. 2021. Laboratory-confirmed SARS-CoV-2 reinfection in the population treated at social security. *Respir Med Case Rep* **34**:101493.
 137. Peghin M, Bouza E, Fabris M, De Martino M, Palese A, Bontempo G, Graziano E, Gerussi V, Bressan V, Sartor A, Isola M, Tascini C, Curcio F. 2021. Low risk of reinfections and relation with serological response after recovery from the first wave of COVID-19. *Eur J Clin Microbiol Infect Dis* 1–8.
 138. Wilkins JT, Hirschhorn LR, Gray EL, Wallia A, Carnethon M, Zembower TR, Ho J, DeYoung BJ, Zhu A, Torvik LJR, Taiwo B, Evans CT. 2021. Serologic Status and SARS CoV-2 Infection over 6-Months of Follow-Up in Healthcare Workers in Chicago: A Cohort Study. *Infect Control Hosp Epidemiol* 1–29.
 139. Ali AM, Ali KM, Fatah MH, Tawfeeq HM, Rostam HM. 2021. SARS-CoV-2 reinfection in patients negative for immunoglobulin G following recovery from COVID-19. *New Microbes New Infect* **43**:100926.
 140. Ringlander J, Olausson J, Nyström K, Härnqvist T, Jakobsson HE, Lindh M. 2021. Recurrent and per-

- sistent infection with SARS-CoV-2 - epidemiological data and case reports from Western Sweden, 2020. *Infect Dis (Lond)*. 1–8
141. Dobaño C, Ramírez-Morros A, Alonso S, Vidal-Alaball J, Ruiz-Olalla G, Vidal M, Rubio R, Cascant E, Parras D, Rodrigo Melero N, Serra P, Carolis C, Santamaria P, Forcada A, Mendioroz J, Aguilar R, Moncunill G, Ruiz-Comellas A. 2021. Persistence and baseline determinants of seropositivity and reinfection rates in health care workers up to 12.5 months after COVID-19. *BMC Med* **19**(1):155.
 142. Sánchez-Montalvá A, Fernández-Naval C, Antón A, Durà X, Vimes A, Silgado A, Velásquez-Orozco F, Espinosa-Pereiro J, Salvador F, Pumarola T, Almirante B, Esperalba J. 2021. Risk of SARS-CoV-2 Infection in Previously Infected and Non-Infected Cohorts of Health Workers at High Risk of Exposure. *J Clin Med* **10**(9):1968.
 143. Lutrick K, Ellingson KD, Baccam Z, Rivers P, Beitel S, Parker J, Hollister J, Sun X, Gerald JK, Komatsu K, Kim E, LaFleur B, Grant L, Yoo YM, Kumar A, Mayo Lamberte J, Cowling BJ, Cobey S, Thornburg NJ, Meece JK, Kutty P, Nikolich-Zugich J, Thompson MG, Burgess JL. 2021. COVID-19 Infection, Reinfection, and Vaccine Effectiveness in a Prospective Cohort of Arizona Frontline/Essential Workers: The AZ HEROES Research Protocol. *JMIR Res Protoc* doi: 10.2196/28925
 144. Crellen T, Pi L, Davis EL, Pollington TM, Lucas TCD, Ayabina D, Borlase A, Toor J, Prem K, Medley GF, Klepac P, Déirdre Hollingsworth T. 2021. Dynamics of SARS-CoV-2 with waning immunity in the UK population. *Philos Trans R Soc Lond B Biol Sci* **376**(1829):20200274
 145. Breathnach AS, Riley PA, Cotter MP, Houston AC, Habibi MS, Planche TD. 2021. Prior COVID-19 significantly reduces the risk of subsequent infection, but reinfections are seen after eight months. *J Infect* **82**(4):e11–e12.
 146. O Murchu E, Byrne P, Carty PG, De Gascun C, Keogan M, O'Neill M, Harrington P, Ryan M. 2021. Quantifying the risk of SARS-CoV-2 reinfection over time. *Rev Med Virol* e2260
 147. Leidi A, Koegler F, Dumont R, Dubos R, Zaballa ME, Piumatti G, Coen M, Berner A, Darbellay Farhoumand P, Vetter P, Vuilleumier N, Kaiser L, Courvoisier D, Azman AS, Guessous I, Stringhini S; SEROCov-POP study group. 2021. Risk of reinfection after seroconversion to SARS-CoV-2: A population-based propensity-score matched cohort study. *Clin Infect Dis* ciab495.
 148. Iruretagoyena M, Vial MR, Spencer-Sandino M, Gaete P, Peters A, Delgado I, Perez I, Calderon C, Porte L, Legarraga P, Anderson A, Aguilera X, Vial P, Weitzel T, Munita JM. 2021. Longitudinal assessment of SARS-CoV-2 IgG seroconversion among front-line healthcare workers during the first wave of the Covid-19 pandemic at a tertiary-care hospital in Chile. *BMC Infect Dis* **21**(1):478
 149. Turner JS, Kim W, Kalaidina E, Goss CW, Rauseo AM, Schmitz AJ, Hansen L, Haile A, Klebert MK, Pusic I, O'Halloran JA, Presti RM, Ellebedy AH. 2021. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. *Nature* **595**(7867):421–425.
 150. Qureshi AI, Baskett WI, Huang W, Lobanova I, Naqvi SH, Shyu CR. 2021. Re-infection with SARS-CoV-2 in Patients Undergoing Serial Laboratory Testing. *Clin Infect Dis* ciab345
 151. Zare F, Teimouri M, Khosravi A, Rohani-Rasaf M, Chaman R, Hosseinzadeh A, Jamali Atergeleh H, Binesh E, Emamian MH. 2021. COVID-19 re-infection in Shahroud, Iran: a follow-up study. *Epidemiol Infect* **149**:e159.
 152. Fabiánová K, Kyncl J, Vlcková I, Jirincová H, Košťálová J, Liptáková M, Orlíková H, Šebestová H, Limberková R, Macková B, Malý M. 2021. COVID-19 reinfections. *Epidemiol Mikrobiol Imunol* **70**(1):62–67.
 153. Davido B, De Truchis P, Lawrence C, Annane D, Domart-Rancon M, Gault E, Saleh-Mghir A, Delarocque-Astagneau E, Gautier S. 2021. SARS-CoV-2 reinfections among hospital staff in the greater Paris area. *J Travel Med* **28**(4):taab058.
 154. Brouqui P, Colson P, Melenotte C, Houhamdi L, Bedotto M, Devaux C, Gautret P, Million M, Parola P, Stoupan D, La Scola B, Lagier JC, Raoult D. 2021. COVID-19 re-infection. *Eur J Clin Invest* **51**(5):e13537
 155. Dimeglio C, Herin F, Miedougé M, Martin-Blondel G, Soulat JM, Izopet J. 2021. Protection of healthcare workers against SARS-CoV-2 reinfection. *Clin Infect Dis* ciab069.
 156. Breathnach AS, Duncan CJA, Bouzidi KE, Hanrath AT, Payne BAI, Randell PA, Habibi MS, Riley PA, Planche TD, Busby JS, Sudhanva M, Pallett SJC, Kelleher WP. 2021. Prior COVID-19 protects against reinfection, even in the absence of detectable antibodies. *J Infect* **83**(2):237–279.
 157. Rennert L, McMahan C. 2021. Risk of SARS-CoV-2 reinfection in a university student population. *Clin Infect Dis* ciab454
 158. Abu-Raddad LJ, Chemaitelly H, Coyle P, Malek JA, Ahmed AA, Mohamoud YA, Younuskunju S, Ayoub HH, Al Kanaani Z, Al Kuwari E, Butt AA, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul Rahim HF, Nasrallah GK, Yassine HM, Al Kuwari MG, Al Romaihi HE, Al-Thani MH, Al Khal A, Bertollini R. 2021. SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. *EClinicalMedicine* **35**:100861
 159. Hanrath AT, Payne BAI, Duncan CJA. 2021. Prior SARS-CoV-2 infection is associated with protection

- against symptomatic reinfection. *J Infect* **82**(4):e29–e30.
160. Lumley SF, O'Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB, Marsden BD, Cox S, James T, Warren F, Peck LJ, Ritter TG, de Toledo Z, Warren L, Axten D, Cornall RJ, Jones EY, Stuart DI, Sreaton G, Ebner D, Hoosdally S, Chand M, Crook DW, O'Donnell AM, Conlon CP, Pouwels KB, Walker AS, Peto TEA, Hopkins S, Walker TM, Jeffery K, Eyre DW; Oxford University Hospitals Staff Testing Group. 2021. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. *N Engl J Med* **384**(6):533–540.
 161. Hamed E, Sedeeq S, Alnuaimi AS, Syed M, ElHamid MA, Alemrayat B, Mukhtar A, AlFehaidi A, A/Qotba H. 2021. Rates of recurrent positive SARS-CoV-2 swab results among patients attending primary care in Qatar. *J Infect* **82**(4):84–123.
 162. Addetia A, Crawford KHD, Dingens A, Zhu H, Roychoudhury P, Huang ML, Jerome KR, Bloom JD, Greninger AL. 2020. Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate. *J Clin Microbiol* **58**(11):e02107–20.
 163. Mack CD, Tai C, Sikka R, Grad YH, Maragakis LL, Grubaugh ND, Anderson DJ, Ho D, Merson M, Samant RM, Fauver JR, Barrett J, Sims L, DiFiori J. 2021. SARS-CoV-2 Reinfection: A Case Series from a 12-Month Longitudinal Occupational Cohort. *Clin Infect Dis* ciab738
 164. Abu-Raddad LJ, Chemaitelly H, Bertollini R; National Study Group for COVID-19 Epidemiology. 2021. Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections. *N Engl J Med* NEJM2108120
 165. Bean DJ, Monroe J, Turcinovic J, Moreau Y, Connor JH, Sagar M. 2021. SARS-CoV-2 reinfection associates with unstable housing and occurs in the presence of antibodies. *Clin Infect Dis* ciab940.
 166. Mensah AA, Campbell H, Stowe J, Seghezze G, Simmons R, Lacy J, Bukasa A, O'Boyle S, Ramsay ME, Brown K, Ladhani S. 2021. Risk of SARS-CoV-2 reinfections in children: prospective national surveillance, January 2020 to July 2021, England. *medRxiv* 2021.12.10.21267372
 167. Levin-Rector A, Firestein L, McGibbon E, Sell J, Lim S, Lee EH, Weiss D, Geevarughese A, Zucker JR, Greene SK. 2021. Reduced Odds of SARS-CoV-2 Reinfection after Vaccination among New York City Adults, June–August 2021. *medRxiv* 2021.12.09.21267203
 168. Malhotra S, Mani K, Lodha R, Bakhshi S, Mathur VP, Gupta P, Kedia S, Sankar J, Kumar P, Kumar A, Ahuja V, Sinha S, Guleria R; COVID Reinfection AIIMS Consortium, Dua A, Ahmad S, Sathiyamoorthy R, Sharma A, Sakya T, Gaur V, Chaudhary S, Sharma S, Madan D, Gupta A, Virmani S, Gupta A, Yadav N, Sachdeva S, Sharma S, Singh S, Pandey A, Singh M, Jhurani D, Sarkar S, Lokade AK, Mohammad A, Pandit S, Dubey R, Singh AK, Gohar N, Soni D, Bhattacharyya A, Rai S, Tummala S, Gupta I, Shukla S. 2022. SARS-CoV-2 Reinfection Rate and Estimated Effectiveness of the Inactivated Whole Virion Vaccine BBV152 Against Reinfection Among Health Care Workers in New Delhi, India. *JAMA Netw Open* **5**(1):e2142210
 169. Mao Y, Wang W, Ma J, Wu S, Sun F. 2021. Reinfection rates among patients previously infected by SARS-CoV-2: systematic review and meta-analysis. *Chin Med J (Engl)* **135**(2):145–152.
 170. Salehi-Vaziri M, Pouriayevali MH, Fotouhi F, Jalali T, Banifazl M, Farahmand B, Sadat Larijani M, Ahmadi Z, Fereydouni Z, Tavakoli M, Karami A, Azad-Manjiri S, Yektay Sanati P, Dahmardeh S, Nemati AH, Sajadi M, Kashanian S, Ramezani A. 2021. SARS-CoV-2 reinfection rate in Iranian COVID-19 cases within one-year follow-up. *Microb Pathog* **161**(Pt B):105296
 171. Mensah AA, Lacy J, Stowe J, Seghezze G, Sachdeva R, Simmons R, Bukasa A, O'Boyle S, Andrews N, Ramsay M, Campbell H, Brown K. 2022. Disease severity during SARS-COV-2 reinfection: a nationwide study. *J Infect* S0163-4453(22)00010-X
 172. McKeigue PM, McAllister DA, Robertson C, Stockton D, Colhoun HM, for the PHS COVID-19 Epidemiology and Research Cell. 2021. Reinfection with SARS-CoV-2: outcome, risk factors and vaccine efficacy in a Scottish cohort. *medRxiv* 2021.11.23.21266574
 173. Maier HE, Balmaseda A, Ojeda S, Cerpas C, Sanchez N, Plazaola M, van Bakel H, Kubale J, Lopez R, Saborio S, Barilla C, PSP Study Group, Harris E, Kuan G, Gordon A. 2021. An immune correlate of SARS-CoV-2 infection and severity of reinfections. *medRxiv* 2021.11.23.21266767
 174. Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Ash N, Alroy-Preis S, Huppert A, Milo R. 2021. Protection and waning of natural and hybrid COVID-19 immunity. *medRxiv* 2021.12.04.21267114
 175. Chivese T, Matizanadzo JT, Musa OAH, Hindy G, Furuya-Kanamori L, Islam N, Al-Shebly R, Shalaby R, Habibullah M, Al-Marwani T, Hourani RF, Nawaz AD, Haider MZ, Emara MM, Cyprian F, Doi SAR. 2021. The prevalence of adaptive immunity to COVID-19 and reinfection after recovery – a comprehensive systematic review and meta-analysis. *medRxiv* 2021.09.03.21263103
 176. Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, Laloo U, Masilela MSL, Moodley D, Hanley S, Fouche L, Louw C, Tameris M, Singh N, Goga A, Dheda K, Grobbelaar C, Kruger G, Carrim-Ganey N, Baillie V, de Oliveira T, Lombard Koen A, Lombaard JJ, Mngqibisa R, Bhorat AE, Benadé G, Laloo N, Pitsi A, Vollgraaff PL, Luabeya A, Esmail A,

- Petrick FG, Oommen-Jose A, Foulkes S, Ahmed K, Thombrayil A, Fries L, Cloney-Clark S, Zhu M, Bennett C, Albert G, Faust E, Plested JS, Robertson A, Neal S, Cho I, Glenn GM, Dubovsky F, Madhi SA; 2019nCoV-501 Study Group. 2021. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. *N Engl J Med* **384**(20):1899–1909.
177. Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, Doolabh D, Pillay S, San EJ, Msomi N, Mlisana K, von Gottberg A, Walaza S, Alalam M, Ismail A, Mohale T, Glass AJ, Engelbrecht S, Van Zyl G, Preiser W, Petruccione F, Sigal A, Hardie D, Marais G, Hsiao NY, Korsman S, Davies MA, Tyers L, Mudau I, York D, Maslo C, Goedhals D, Abrahams S, Laguda-Akingba O, Alisoltani-Dehkordi A, Godzik A, Wibmer CK, Sewell BT, Lourenço J, Alcántara LCJ, Kosakovsky Pond SL, Weaver S, Martin D, Lessells RJ, Bhiman JN, Williamson C, de Oliveira T. 2021. Detection of a SARS-CoV-2 variant of concern in South Africa. *Nature* **592**(7854):438–443.
 178. Muik A, Lui BG, Wallisch AK, Bacher M, Mühl J, Reinholz J, Ozhelvaci O, Beckmann N, Güimil Garcia RC, Poran A, Shpyro S, Finlayson A, Cai H, Yang Q, Swanson KA, Türeci Ö, Sahin U. 2022. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera. *Science* **375**(6581):678–680
 179. Dejnirattisai W, Huo J, Zhou D, Zahradník J, Supasa P, Liu C, Duyvesteyn HME, Ginn HM, Mentzer AJ, Tuekprakhon A, Nutalai R, Wang B, Djikajite A, Khan S, Avinoam O, Bahar M, Skelly D, Adele S, Johnson SA, Amini A, Ritter TG, Mason C, Dold C, Pan D, Assadi S, Bellass A, Omo-Dare N, Koeckerling D, Flaxman A, Jenkin D, Aley PK, Voysey M, Costa Clemens SA, Naveca FG, Nascimento V, Nascimento F, Fernandes da Costa C, Resende PC, Pauvolid-Correa A, Siqueira MM, Baillie V, Serafin N, Kwatra G, Da Silva K, Madhi SA, Nunes MC, Malik T, Openshaw PJM, Baillie JK, Semple MG, Townsend AR, Huang KA, Tan TK, Carroll MW, Klenerman P, Barnes E, Dunachie SJ, Constantinides B, Webster H, Crook D, Pollard AJ, Lambe T; OPTIC Consortium; ISARIC4C Consortium, Paterson NG, Williams MA, Hall DR, Fry EE, Mongkolsapaya J, Ren J, Schreiber G, Stuart DI, Sreaton GR. 2022. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. *Cell* **185**(3):467–484.e15
 180. Hui KPY, Ho JCW, Cheung MC, Ng KC, Ching RHH, Lai KL, Kam TT, Gu H, Sit KY, Hsin MKY, Au TWK, Poon LLM, Peiris M, Nicholls JM, Chan MCW. 2022. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. *Nature* doi: 10.1038/s41586-022-04479-6.
 181. Meng B, Abdullahi A, Ferreira IATM, Goonawardane N, Saito A, Kimura I, Yamasoba D, Gerber PP, Fatihi S, Rathore S, Zepeda SK, Papa G, Kemp SA, Ikeda T, Toyoda M, Tan TS, Kuramochi J, Mitsunaga S, Ueno T, Shirakawa K, Takaori-Kondo A, Brevini T, Mallery DL, Charles OJ; CITIID-NIHR BioResource COVID- Collaboration; Genotype to Phenotype Japan (GP-Japan) Consortium members; Ecuador-COVID19 Consortium, Bowen JE, Joshi A, Walls AC, Jackson L, Martin D, Smith KGC, Bradley J, Briggs JAG, Choi J, Madissoon E, Meyer K, Mlcochova P, Ceron-Gutierrez L, Doffinger R, Teichmann SA, Fisher AJ, Pizzuto MS, de Marco A, Corti D, Hosmillo M, Lee JH, James LC, Thukral L, Velesler D, Sigal A, Sampaziotis F, Goodfellow IG, Matheson NJ, Sato K, Gupta RK. 2022. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity. *Nature* doi: 10.1038/s41586-022-04474-x.
 182. Altarawneh H, Chemaitelly H, Tang P, Hasan MR, Qassim S, Ayoub HH, AlMukdad S, Yassine HM, Benslimane FM, Al Khatib HA, Coyle P, Al Kanaani Z, Al Kuwari E, Jeremijenko A, Hassan Kaleeckal A, Nizar Latif A, Mohammad Shaik R, Abdul Rahim HF, Nasrallah GK, Al Kuwari MG, Butt AA, Al Romaihi HE, Al-Thani MH, Al Khal A, Bertollini R, Abu-Raddad LJ. 2022. Protection afforded by prior infection against SARS-CoV-2 reinfection with the Omicron variant. *medRxiv* 2022.01.05.22268782
 183. Nunes MC, Sibanda S, Baillie VL, Kwatra G, Aguas R, Madhi SA, the Wits VIDA HCW Study Group. 2022. SARS-CoV-2 Omicron symptomatic infections in previously infected or vaccinated South African health-care workers. *medRxiv* 2022.02.04.22270480
 184. Lyngse FP, Mortensen LH, Denwood MJ, Christiansen LE, Moller CH, Skov RL, Spiess K, Fomsgaard A, Lassaunière MM, Rasmussen M, Stegger M, Nielsen C, Sieber RN, Cohen AS, Moller FT, Overvad M, Molbak K, Krause TG, Kirkeby CT. 2021. SARS-CoV-2 Omicron VOC Transmission in Danish Households. *medRxiv* 2021.12.27.21268278
 185. Lacy J, Mensah A, Simmons R, Andrews M, Siddiqui MR, Bukasa A, O’Boyle S, Campbell H, Brown K. 2022. Protective effect of a first SARS-CoV-2 infection from reinfection: a matched retrospective cohort study using PCR testing data in England. *medRxiv* 2022.01.10.22268896;
 186. Rangachev A, Marinov GK, Mladenov M. 2021. The demographic and geographic impact of the COVID pandemic in Bulgaria and Eastern Europe in 2020. *medRxiv* 2021.04.06.21254958
 187. Karlinsky A, Kobak D. 2021. Tracking excess mortality across countries during the COVID-19 pandemic with the World Mortality Dataset. *Elife* **10**:e69336
 188. Shu Y, McCauley J. 2017. GISAID: Global initiative on sharing all influenza data - from vision to reality. *Euro Surveill* **22**(13):30494
 189. Kraemer MUG, Hill V, Ruis C, Dellicour S, Bajaj S, McCrone JT, Baele G, Parag KV, Battle AL, Gutier-

- rez B, Jackson B, Colquhoun R, O’Toole A, Klein B, Vespignani A; COVID-19 Genomics UK (COG-UK) Consortium, Volz E, Faria NR, Aanensen DM, Loman NJ, du Plessis L, Cauchemez S, Rambaut A, Scarpino SV, Pybus OG. 2021. Spatiotemporal invasion dynamics of SARS-CoV-2 lineage B.1.1.7 emergence. 2021. *Science* **373**(6557):889-895
190. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, Pearson CAB, Russell TW, Tully DC, Washburne AD, Wenseleers T, Gimma A, Waites W, Wong KLM, van Zandvoort K, Silverman JD; CMMID COVID-19 Working Group; COVID-19 Genomics UK (COG-UK) Consortium, Diaz-Ordaz K, Keogh R, Eggo RM, Funk S, Jit M, Atkins KE, Edmunds WJ. 2021. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science* **372**(6538):eabg3055
 191. Mlcochova P, Kemp SA, Dhar MS, Papa G, Meng B, Ferreira IATM, Datir R, Collier DA, Albecka A, Singh S, Pandey R, Brown J, Zhou J, Goonawardane N, Mishra S, Whittaker C, Mellan T, Marwal R, Datta M, Sengupta S, Ponnusamy K, Radhakrishnan VS, Abdullahi A, Charles O, Chattopadhyay P, Devi P, Caputo D, Peacock T, Wattal C, Goel N, Satwik A, Vaishya R, Agarwal M; Indian SARS-CoV-2 Genomics Consortium (INSACOG); Genotype to Phenotype Japan (G2P-Japan) Consortium; CITIID-NIHR BioResource COVID-19 Collaboration, Mavousian A, Lee JH, Bassi J, Silacci-Fegni C, Saliba C, Pinto D, Irie T, Yoshida I, Hamilton WL, Sato K, Bhatt S, Flaxman S, James LC, Corti D, Piccoli L, Barclay WS, Rakshit P, Agrawal A, Gupta RK. 2021. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. *Nature* **599**(7883):114–119.
 192. Hightower AW, Orenstein WA, Martin SM. 1988. Recommendations for the use of Taylor series confidence intervals for estimates of vaccine efficacy. *Bull World Health Organ* **66**(1):99–105.
 193. Cohn BA, Cirillo PM, Murphy CC, Krigbaum NY, Wallace AW. 2022. SARS-CoV-2 vaccine protection and deaths among US veterans during 2021. *Science* **375**(6578):331-336.
 194. Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Alroy-Preis S, Ash N, Huppert A, Milo R. 2021. Protection against Covid-19 by BNT162b2 Booster across Age Groups. 2021. *N Engl J Med* **385**(26):2421–2430.
 195. Collier DA, Ferreira IATM, Kotagiri P, Datir RP, Lim EY, Touizer E, Meng B, Abdullahi A; CITIID-NIHR BioResource COVID-19 Collaboration, Elmer A, Kingston N, Graves B, Le Gresley E, Caputo D, Bergamaschi L, Smith KGC, Bradley JR, Ceron-Gutierrez L, Cortes-Acevedo P, Barcenas-Morales G, Linterman MA, McCoy LE, Davis C, Thomson E, Lyons PA, McKinney E, Doffinger R, Wills M, Gupta RK. 2021. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. *Nature* **596**(7872):417–422.